A Phase 2 interventional study of CK-3773274 (5 - 15 mg) and CK-3773274 (10 - 30 mg) in Hypertrophic Cardiomyopathy (HCM), sponsored by Cytokinetics. Completed at 22 sites in 4 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by Cytokinetics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing aficamten in Cardiomyopathy, Hypertrophic — 2 open to participants now, 5 under way, 4 of them phase 3. aficamten · Cardiomyopathy, Hypertrophic.
Among the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, this one is the 6th largest by enrollment, is the only one that started in 2020, is the only one in phase 2, and was the 2nd registered.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →2 of the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic are open now, in 12 countries. Recruiting first, the newest first:
Oregon Health and Science University · Sites in United States
Ages 18–90
Cytokinetics · Sites in United States, Argentina, Australia and 16 more countries
Ages 18–85
By country, each count listing its studies:
aficamten: first FDA approval 2025 (MYQORZO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 7 · Phase 4 1
First in 2018; this study’s year is marked. 1 started in 2020.
This study's enrollment of 96 is above the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 96 across the 11 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 4 most frequent:
Cytokinetics is the lead sponsor of 41 studies on the registry; 3 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 7 (64%) have results posted.
Cytokinetics has 7 studies filed under Cardiomyopathy, Hypertrophic — fewer than ten, so there is no comparison to draw.
1 of the studies testing aficamten in Cardiomyopathy, Hypertrophic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07600177Oregon Health and Science UniversityMavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being performed to understand the effect of different doses of CK-3773274 on patients with hypertrophic cardiomyopathy (HCM).
This was a Phase 2, multi-center, randomized, placebo-controlled, double-blind, dose-finding study in participants with symptomatic HCM. The study consisted of 4 cohorts. For Cohorts 1 and 2, participants with obstructive HCM (oHCM) and not receiving disopyramide were randomized 2:1 to active or placebo treatment and received up to 3 escalating doses of aficamten (5, 10, and 15 mg once daily in Cohort 1 and 10, 20, and 30 mg once daily in Cohort 2) or placebo based on site-read echocardiographic guidance. Cohort 3 consisted of participants with oHCM whose background HCM therapy included disopyramide. All participants in Cohort 3 received up to 3 escalating doses of aficamten (5, 10, and 15 mg once daily) based on echocardiographic guidance. Cohort 4 consisted of participants with non-obstructive HCM (nHCM) on standard of care background therapy. Cohort 4 participants received up to 3 doses of aficamten (5, 10, and 15 mg once daily), titrated based on site-read echocardiographic guidance.
In all 4 cohorts, treatment duration was 10 weeks with a 4-week follow-up period after the last dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with HCM per the following criteria:
For Cohorts 1, 2 and 3 has LVOT-G during screening as follows:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received CK-3773274 doses of 5 - 15 mg once daily with dose levels guided by echocardiography assessments for up to 10 weeks
Drug: CK-3773274 (5 - 15 mg)
Participants received placebo once daily for up to 10 weeks
Drug: Placebo for CK-3773274
Participants received CK-3773274 doses 10 - 30 mg once daily with dose levels guided by echocardiography assessments for up to 10 weeks
Drug: CK-3773274 (10 - 30 mg)
Participants received placebo once daily for up to 10 weeks
Drug: Placebo for CK-3773274
Participants received CK-3773274 doses 5 - 15 mg once daily with dose levels guided by echocardiography assessments for up to 10 weeks while taking disopyramide
Drug: CK-3773274 (5 - 15 mg)
Participants received CK-3773274 doses of 5 - 15 mg once daily with dose levels guided by echocardiography assessments for up to 10 weeks
Drug: CK-3773274 (5 - 15 mg)
CK-3773274 tablets administered orally once daily
CK-3773274 tablets administered orally once daily
Placebo administered orally once daily
Incidence of Adverse Events (AEs)
Participant incidence of reported AEs to determine the safety and tolerability of aficamten in participants with HCM.
Time frame: 14 weeks
Incidence of Left Ventricular Ejection Fraction (LVEF) < 50%
Participant incidence of LVEF \< 50% as assessed by the core laboratory assessment.
Time frame: 14 weeks
Incidence of Serious Adverse Events (SAEs)
Participant incidence of reported SAEs to determine the safety and tolerability of aficamten in participants with symptomatic HCM.
Time frame: 14 weeks
Slope of the Relationship of the Plasma Concentration of CK-3773274 to the Change From Baseline in the Resting Left Ventricular Outflow Track Gradient (LVOT-G)
Concentration-response relationship of CK-3773274 on the resting LVOT-G on echocardiogram over 10 weeks of treatment in participants with (oHCM) obstructive hypertrophic cardiomyopathy (oHCM) (Cohorts 1, 2, 3 only)
Time frame: Baseline and 10 weeks
Slope of the Relationship of the Plasma Concentration of CK-3773274 to the Change From Baseline in the Post-Valsalva LVOT-G
Concentration-response relationship of CK-3773274 on the post-Valsalva LVOT-G on echocardiogram over 10 weeks of treatment in participants with oHCM (Cohorts 1, 2, 3 only)
Time frame: Baseline and 10 Weeks
Change From Baseline in Resting LVOT-G Over Time as a Function of Dose.
Dose response relationship on resting LVOT-G of CK-3773274 in participants with oHCM (Cohorts 1, 2, 3 only)
Time frame: Baseline and 10 Weeks
Change From Baseline in Post-Valsalva LVOT-G Over Time as a Function of Dose.
Dose response relationship of CK-3773274 on post-Valsalva LVOT-G in participants with symptomatic oHCM (Cohorts 1, 2, 3 only)
Time frame: 10 weeks
Slope of the Relationship of the Plasma Concentration of CK-3773274 to the Change From Baseline in the Resting LVEF
Concentration-response relationship of CK-3773274 on LVEF over 10 weeks of treatment in participants with HCM
Time frame: Day 1 to End of Study (EOS) (Week 14)
| Milestone | Cohort 1 (oHCM) - Aficamten | Cohort 1 (oHCM) - Placebo | Cohort 2 (oHCM) - Aficamten | Cohort 2 (oHCM) - Placebo | Cohort 3 (oHCM) - Aficamten & Background Disopyramide | Cohort 4 (nHCM) - Aficamten |
|---|---|---|---|---|---|---|
| Started | 14 | 8 | 14 | 6 | 13 | 41 |
| Completed | 14 | 6 | 14 | 6 | 13 | 39 |
| Not completed | 0 | 2 | 0 | 0 | 0 | 2 |
| Withdrew: Protocol violation | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 1 |
Participant incidence of reported AEs to determine the safety and tolerability of aficamten in participants with HCM.
| Participants | Cohort 1 (oHCM) - Aficamten | Cohort 1 (oHCM) - Placbo | Cohort 2 (oHCM) - Aficamten | Cohort 2 (oHCM) - Placebo | Cohort 3 (oHCM) - Aficamten & Background Disopyramide | Cohort 4 (nHCM) - Aficamten |
|---|---|---|---|---|---|---|
| Incidence of Adverse Events (AEs) | 10 | 7 | 11 | 4 | 9 | 28 |
Participant incidence of LVEF \< 50% as assessed by the core laboratory assessment.
| Participants | Cohort 1 (oHCM) - Aficamten | Cohort 1 (oHCM) - Placebo | Cohort 2 (oHCM) - Aficamten | Cohort 2 (oHCM) - Placebo | Cohort 3 (oHCM) - Aficamten & Background Disopyramide | Cohort 4 (nHCM) - Aficamten |
|---|---|---|---|---|---|---|
| Incidence of Left Ventricular Ejection Fraction (LVEF) < 50% | 0 | 0 | 2 | 0 | 0 | 3 |
Participant incidence of reported SAEs to determine the safety and tolerability of aficamten in participants with symptomatic HCM.
| Participants | Cohort 1 (oHCM) - Aficamten | Cohort 1 (oHCM) - Placebo | Cohort 2 (oHCM) - Aficamten | Cohort 2 (oHCM) - Placebo | Cohort 3 (oHCM) - Aficamten & Background Disopyramide | Cohort 4 (nHCM) - Aficamten |
|---|---|---|---|---|---|---|
| Incidence of Serious Adverse Events (SAEs) | 1 | 1 | 1 | 0 | 0 | 4 |
Concentration-response relationship of CK-3773274 on the resting LVOT-G on echocardiogram over 10 weeks of treatment in participants with (oHCM) obstructive hypertrophic cardiomyopathy (oHCM) (Cohorts 1, 2, 3 only)
| mmHg per ng/ML | Cohort 1 (oHCM) - Aficamten | Cohort 2 (oHCM) | Cohort 3 (oHCM) - Aficamten & Background Disopyramide |
|---|---|---|---|
| Slope of the Relationship of the Plasma Concentration of CK-3773274 to the Change From Baseline in the Resting Left Ventricular Outflow Track Gradient (LVOT-G) | -0.1018 (-0.1394 to -0.0642) | -0.0173 (-0.0325 to -0.0021) | -0.0582 (-0.1029 to -0.0135) |
Concentration-response relationship of CK-3773274 on the post-Valsalva LVOT-G on echocardiogram over 10 weeks of treatment in participants with oHCM (Cohorts 1, 2, 3 only)
| mmHg per ng/ML | Cohort 1 (oHCM) - Aficamten | Cohort 2 (oHCM) - Aficamten | Cohort 3 (oHCM) - Aficamten & Background Disopyramide |
|---|---|---|---|
| Slope of the Relationship of the Plasma Concentration of CK-3773274 to the Change From Baseline in the Post-Valsalva LVOT-G | -0.0902 (-0.1391 to -0.0413) | -0.0538 (-0.0765 to -0.0310) | -0.1396 (-0.2144 to -0.0649) |
Dose response relationship on resting LVOT-G of CK-3773274 in participants with oHCM (Cohorts 1, 2, 3 only)
| mmHg | Cohort 1 (oHCM) - Aficamten | Cohort 1 (oHCM) - Placebo | Cohort 2 (oHCM) - Aficamten | Cohort 2 (oHCM) - Placebo | Cohort 3 (oHCM) - Aficamten & Background Disopyramide |
|---|---|---|---|---|---|
| Placebo | — | -19.2 ± 30.3 | — | -0.5 ± 11.5 | — |
| 5 mg QD | -23.8 ± 17.0 | — | — | — | -16.0 ± 15.3 |
| 10 mg QD | -48.6 ± 31.1 | — | -53.1 ± 38.9 | — | -22.6 ± 14.3 |
| 15 mg QD | -45.5 ± 27.2 | — | — | — | -39.5 ± 26.9 |
| 20 mg QD | — | — | -30.8 ± 27.7 | — | — |
| 30 mg QD | — | — | -3.1 ± NA | — | — |
Dose response relationship of CK-3773274 on post-Valsalva LVOT-G in participants with symptomatic oHCM (Cohorts 1, 2, 3 only)
| mmHg | Cohort 1 (oHCM) - Aficamten | Cohort 1 (oHCM) - Placebo | Cohort 2 (oHCM) - Aficamten | Cohort 2 (oHCM) - Placebo | Cohort 3 (oHCM) - Aficamten & Background Disopyramide |
|---|---|---|---|---|---|
| Placebo | — | -10.5 ± 24.9 | — | -3.0 ± 8.6 | — |
| 5 mg QD | -23.1 ± 28.7 | — | — | — | -43.8 ± 40.6 |
| 10 mg QD | -35.1 ± 32.1 | — | -66.7 ± 41.3 | — | -13.5 ± 18.1 |
| 15 mg QD | -48.2 ± 20.4 | — | — | — | -35.7 ± 44.1 |
| 20 mg QD | — | — | -38.4 ± 37.5 | — | — |
| 30 mg QD | — | — | 18.6 ± NA | — | — |
Concentration-response relationship of CK-3773274 on LVEF over 10 weeks of treatment in participants with HCM
| percentage per ng/ML | Cohort 1 (oHCM) - Aficamten | Cohort 2 (oHCM) - Aficamten | Cohort 3 (oHCM) - Aficamten & Background Disopyramide | Cohort 4 (nHCM) - Aficamten |
|---|---|---|---|---|
| Slope of the Relationship of the Plasma Concentration of CK-3773274 to the Change From Baseline in the Resting LVEF | -0.0222 (-0.0331 to -0.0114) | -0.0200 (-0.0276 to -0.0124) | -0.0154 (-0.0285 to -0.0023) | -0.0105 (-0.0153 to -0.0056) |
Collected over Up to 14 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 (oHCM) - Aficamten | 0/14 (0%) | 1/14 (7.1%) | 10/14 (71.4%) |
| Cohort 1 (oHCM) - Placebo | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Cohort 2 (oHCM) - Aficamten | 0/14 (0%) | 1/14 (7.1%) | 11/14 (78.6%) |
| Cohort 2 (oHCM) - Placebo | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Cohort 3 (oHCM) - Aficamten & Background Disopyramide | 0/13 (0%) | 0/13 (0%) | 9/13 (69.2%) |
| Cohort 4 (nHCM) - Aficamten | 1/41 (2.4%) | 4/41 (9.8%) | 26/41 (63.4%) |
| Event | Cohort 1 (oHCM) - Aficamten | Cohort 1 (oHCM) - Placebo | Cohort 2 (oHCM) - Aficamten | Cohort 2 (oHCM) - Placebo | Cohort 3 (oHCM) - Aficamten & Background Disopyramide | Cohort 4 (nHCM) - Aficamten |
|---|---|---|---|---|---|---|
| HypotensionVascular disorders | 0/14 | 1/7 | 0/14 | 0/6 | 0/13 | 0/41 |
| Stress cardiomyopathyCardiac disorders | 0/14 | 1/7 | 0/14 | 0/6 | 0/13 | 0/41 |
| SyncopeNervous system disorders | 0/14 | 1/7 | 0/14 | 0/6 | 0/13 | 0/41 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/14 | 1/7 | 0/14 | 0/6 | 0/13 | 0/41 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 0/14 | 1/7 | 0/14 | 0/6 | 0/13 | 0/41 |
| Acute coronary syndromeCardiac disorders | 0/14 | 0/7 | 1/14 | 0/6 | 0/13 | 0/41 |
| Back painMusculoskeletal and connective tissue disorders | 1/14 | 0/7 | 0/14 | 0/6 | 0/13 | 0/41 |
| Atrial fibrillationCardiac disorders | 0/14 | 0/7 | 0/14 | 0/6 | 0/13 | 1/41 |
| Cardiac arrestCardiac disorders | 0/14 | 0/7 | 0/14 | 0/6 | 0/13 | 1/41 |
| Myasthenia gravisImmune system disorders | 0/14 | 0/7 | 0/14 | 0/6 | 0/13 | 1/41 |
| Event | Cohort 1 (oHCM) - Aficamten | Cohort 1 (oHCM) - Placebo | Cohort 2 (oHCM) - Aficamten | Cohort 2 (oHCM) - Placebo | Cohort 3 (oHCM) - Aficamten & Background Disopyramide | Cohort 4 (nHCM) - Aficamten |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/14 | 3/7 | 0/14 | 1/6 | 2/13 | 1/41 |
| Dry mouthGastrointestinal disorders | 1/14 | 0/7 | 0/14 | 2/6 | 0/13 | 0/41 |
| DizzinessNervous system disorders | 3/14 | 1/7 | 2/14 | 0/6 | 0/13 | 4/41 |
| FatigueGeneral disorders | 1/14 | 1/7 | 0/14 | 0/6 | 1/13 | 7/41 |
| NauseaGastrointestinal disorders | 0/14 | 1/7 | 0/14 | 1/6 | 1/13 | 3/41 |
| BursitisMusculoskeletal and connective tissue disorders | 0/14 | 0/7 | 0/14 | 1/6 | 0/13 | 0/41 |
| Dry eyeEye disorders | 0/14 | 0/7 | 0/14 | 1/6 | 0/13 | 0/41 |
| Weight increasedInvestigations | 0/14 | 0/7 | 0/14 | 1/6 | 0/13 | 0/41 |
| Seasonal allergyImmune system disorders | 0/14 | 0/7 | 0/14 | 1/6 | 0/13 | 0/41 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/14 | 0/7 | 0/14 | 0/6 | 2/13 | 0/41 |
One participant in the placebo group was discontinued from the study prior to receiving treatment.
| Age, Categorical(Participants) | Cohort 1 (oHCM) - Aficamten | Cohort 1 (oHCM) - Placebo | Cohort 2 (oHCM) - Aficamten | Cohort 2 (oHCM) - Placebo | Cohort 3 (oHCM) - Aficamten & Background Disopyramide | Cohort 4 (nHCM) - Aficamten | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 4 | 9 | 6 | 9 | 28 | 64 |
| >=65 years | 6 | 3 | 5 | 0 | 4 | 13 | 31 |
| Sex: Female, Male(Participants) | Cohort 1 (oHCM) - Aficamten | Cohort 1 (oHCM) - Placebo | Cohort 2 (oHCM) - Aficamten | Cohort 2 (oHCM) - Placebo | Cohort 3 (oHCM) - Aficamten & Background Disopyramide | Cohort 4 (nHCM) - Aficamten | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 6 | 11 | 2 | 7 | 24 | 54 |
| Male | 10 | 1 | 3 | 4 | 6 | 17 | 41 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 (oHCM) - Aficamten | Cohort 1 (oHCM) - Placebo | Cohort 2 (oHCM) - Aficamten | Cohort 2 (oHCM) - Placebo | Cohort 3 (oHCM) - Aficamten & Background Disopyramide | Cohort 4 (nHCM) - Aficamten | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 1 | 2 | 3 |
| Not Hispanic or Latino | 14 | 7 | 14 | 6 | 12 | 39 | 92 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 (oHCM) - Aficamten | Cohort 1 (oHCM) - Placebo | Cohort 2 (oHCM) - Aficamten | Cohort 2 (oHCM) - Placebo | Cohort 3 (oHCM) - Aficamten & Background Disopyramide | Cohort 4 (nHCM) - Aficamten | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 | 0 | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 1 | 1 | 8 | 10 |
| White | 14 | 7 | 14 | 5 | 11 | 27 | 78 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Region of Enrollment(Participants) | Cohort 1 (oHCM) - Aficamten | Cohort 1 (oHCM) - Placebo | Cohort 2 (oHCM) - Aficamten | Cohort 2 (oHCM) - Placebo | Cohort 3 (oHCM) - Aficamten & Background Disopyramide | Cohort 4 (nHCM) - Aficamten | Total |
|---|---|---|---|---|---|---|---|
| United States | 13 | 7 | 13 | 5 | 13 | 35 | 86 |
| Spain | 1 | 0 | 0 | 0 | 0 | 5 | 6 |
| Italy | 0 | 0 | 1 | 1 | 0 | 1 | 3 |
| LVEF(%) | Cohort 1 (oHCM) - Aficamten | Cohort 1 (oHCM) - Placebo | Cohort 2 (oHCM) - Aficamten | Cohort 2 (oHCM) - Placebo | Cohort 3 (oHCM) - Aficamten & Background Disopyramide | Cohort 4 (nHCM) - Aficamten | Total |
|---|---|---|---|---|---|---|---|
| Mean | 73.2 ± 5.6 | 76.8 ± 6.7 | 75.4 ± 6.4 | 71.9 ± 4.5 | 74.2 ± 7.5 | 69.8 ± 7.2 | 72.4 ± 7.0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2020 to primary completion in Feb 2023, 37 months.
Results were first posted in Feb 2026, 2 years 11 months after primary completion. A results delay was requested in Nov 2023.
Of 20 phase 2 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's 37 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aficamten
Cardiomyopathy, Hypertrophic →